STOCK TITAN

Jasper Therapeutics (JSPR) Financials

JSPR NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$157.5M n/m YoY
EPS (Diluted) -$7.49 YoY not available
Operating Cash Flow -$48.8M n/m YoY
Market Cap $11.9M as of Nov 19, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JSPR SEC filings page.

This page shows Jasper Therapeutics, Inc. (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI JSPR FY2025

FY2025 shows a business where research spending stays elevated as losses deepen and the balance sheet shifts toward liabilities.

R&D increased 13.0% in FY2025 while operating cash flow reached -$77.2M, linking heavier investment with continued cash consumption rather than near-term operating relief. The clearest operating signal is the rising resource requirement: R&D reached $63.1M, compared with $51.8M in FY2023, while losses also widened.

The financing structure changed materially: liabilities were 88.4% of assets in FY2025, while equity fell 93.3% from FY2024. That combination explains why return on equity reached -1826.1%: the denominator had become very small, making the ratio more a balance-sheet signal than a clean measure of operating performance. The company still reported positive equity of $4.2M, but with substantially less cushion against further losses.

FY2025 financing cash flow was positive at $34.2M while operating cash flow was -$77.2M, so operations were not self-funding and financing remained part of the cash model. Reported liquidity equaled 4.5 months of the latest annual operating outflow, framing liquidity as a funding measure rather than evidence of improved operating economics.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Jasper Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
0/6

Jasper Therapeutics, Inc. passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Jasper Therapeutics, Inc. reported a net loss of $75.8M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$8.0M

Jasper Therapeutics, Inc. generated $8.0M in revenue in Q3 2026.

EBITDA
-$144.2M
YoYn/m
QoQ-1322.4%
5Y CAGRn/m

Jasper Therapeutics, Inc.'s EBITDA was -$144.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 1322.4%.

Net Income
-$144.5M
YoYn/m
QoQn/m
5Y CAGRn/m

Jasper Therapeutics, Inc. reported a net loss of $144.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$10.19

Jasper Therapeutics, Inc. earned -$10.19 per diluted share (EPS) in Q3 2026.

Cash & Balance Sheet

Cash & Debt
$135.3M
YoY+165.9%
QoQ+1750.5%
5Y CAGR+6.0%

Jasper Therapeutics, Inc. held $135.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
1M

Jasper Therapeutics, Inc. had 1M shares outstanding in Q3 2026.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
46.0%

Jasper Therapeutics, Inc.'s gross margin was 46.0% in Q3 2026, indicating the percentage of revenue retained after direct costs.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$8.3M
YoY-42.1%
QoQ+62.2%
5Y CAGR+3.0%

Jasper Therapeutics, Inc. invested $8.3M in research and development in Q3 2026. This represents a decrease of 42.1% from the same quarter a year earlier. Against the prior quarter it is up 62.2%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

JSPR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$8.0MN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue$4.3M-53.8%$3.6M-77.3%$3.6M-62.9%$6.8M$9.3M+6.4%$15.8M$9.8MN/A
Gross Profit$3.7MN/AN/AN/AN/AN/AN/AN/A
R&D Expenses$8.3M-42.1%$5.1M-75.8%$5.8M-64.0%$11.4M-42.5%$14.4M-0.4%$21.2M+87.6%$16.2M+56.9%$19.8M+42.9%
SG&A Expenses$6.4M+33.2%$4.1M-30.7%$5.1M-9.0%$4.5M-18.8%$4.8M-12.1%$5.9M+25.2%$5.6M+18.2%$5.5M+41.7%
Operating Income-$144.2Mn/m-$9.2Mn/m-$11.0Mn/m-$15.8Mn/m-$19.2Mn/m-$27.1Mn/m-$21.8Mn/m-$25.3Mn/m
EBITDA-$144.2Mn/m$11.8Mn/m-$10.9Mn/m-$15.5Mn/m-$19.0Mn/m-$26.8Mn/m-$21.5Mn/m-$25.0Mn/m
Net Income-$144.5Mn/m-$2.8Mn/m-$1.2Mn/m-$9.1Mn/m-$18.7Mn/m-$26.7Mn/m-$21.2Mn/m-$24.3Mn/m
EPS (Basic)-$10.19-$3.00-$1.20$6.90-$32.08-$52.20n/m-$42.30n/m-$49.20n/m
EPS (Diluted)-$10.19-$3.00-$1.20$6.90-$32.08-$52.20n/m-$42.30n/m-$49.20n/m
Diluted Shares (Avg)1M956,565955,727N/A584,056511,132+2.3%500,737+12.7%N/A

Not reported in any period shown, so not listed: Interest Expense, Income Tax.

JSPR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$147.4M+156.5%$11.8M-74.6%$21.2M-63.2%$35.8M-55.2%$57.5M-42.2%$46.5M-59.2%$57.6M-54.3%$79.9M-15.8%
Current Assets$147.3M+169.9%$11.6M-73.1%$20.3M-61.8%$34.6M-54.3%$54.6M-42.4%$43.0M-60.5%$53.2M-55.8%$75.8M-14.8%
Cash & Equivalents$135.3M+165.9%$7.3M-81.5%$14.1M-71.0%$28.7M-59.9%$50.9M-45.0%$39.5M-63.0%$48.8M-58.8%$71.6M-17.6%
Short-Term InvestmentsN/AN/AN/A$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts Receivable$8.0MN/AN/AN/AN/AN/AN/AN/A
Long-Term InvestmentsN/AN/AN/A$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$287.7M+526.7%$10.4M-54.8%$17.8M+15.8%$31.6M+73.5%$45.9M+191.7%$23.0M+68.6%$15.4M+20.6%$18.2M+10.8%
Current Liabilities$13.9M-33.9%$7.8M-61.7%$9.0M-27.1%$13.2M-13.4%$21.0M+68.9%$20.5M+103.6%$12.3M+38.3%$15.2M+23.1%
Non-Current Liabilities$273.8M+1001.3%$2.5M+3.2%$8.8M+191.1%$18.4M+516.7%$24.9M+659.2%$2.5M-30.6%$3.0M-20.9%$3.0M-26.7%
Total Equity-$140.2M-1312.1%$1.4M-94.0%$3.4M-92.0%$4.2M-93.3%$11.6M-86.2%$23.5M-76.6%$42.2M-62.7%$61.7M-21.4%
Retained Earnings-$465.1Mn/m-$320.6Mn/m-$317.8Mn/m-$316.7Mn/m-$307.6Mn/m-$288.8Mn/m-$262.1Mn/m-$240.9Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

JSPR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$5.5Mn/m-$6.9Mn/m-$14.5Mn/m-$21.9Mn/m-$17.0Mn/m-$15.5Mn/m-$22.8Mn/m-$21.1Mn/m
Depreciation & Amortization$16K-92.0%$21.0M+6900.0%$21K-92.5%$290K+18.4%$200K-60.0%$300K0.0%$279K-3.1%$245K-13.4%
Stock-Based CompensationN/AN/A$423K-76.6%N/A$1.4M-28.7%$1.8M+22.6%$1.8M+54.9%N/A
Capital ExpendituresN/AN/AN/AN/A$0N/AN/AN/A
Free Cash FlowN/AN/AN/AN/A-$17.0MN/AN/AN/A
Investing Cash Flow$7.7Mn/mN/AN/A$0n/m$0n/m$1Kn/m$4Kn/m-$76Kn/m
Financing Cash Flow$125.8M+343.2%N/AN/A-$340K-198.6%$28.4M+315322.2%N/AN/A$345Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

JSPR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JSPR quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin46.0%N/AN/AN/AN/AN/AN/AN/A
Operating Margin-1802.2%N/AN/AN/AN/AN/AN/AN/A
Net Margin-1805.7%N/AN/AN/AN/AN/AN/AN/A
Return on EquityN/A-195.3%-81.6pp-34.5%+15.8pp-219.3%-179.8pp-161.9%-139.7pp-113.7%-99.2pp-50.3%-38.2pp-39.4%-18.3pp
Return on Assets-98.0%-65.4pp-23.4%+34.1pp-5.5%+31.3pp-25.4%+5.0pp-32.6%-13.9pp-57.5%-44.7pp-36.9%-26.0pp-30.4%-13.0pp
Current Ratio10.59+8.0x1.48-0.6x2.26-2.1x2.62-2.4x2.59-5.0x2.10-8.7x4.31-9.2x4.98-2.2x
Liabilities-to-EquityN/A7.35+6.4x5.23+4.9x7.62+7.3x3.97+3.8x0.98+0.8x0.36+0.3x0.30+0.1x
Asset Turnover0.05N/AN/AN/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Jasper Therapeutics, Inc. JSPR FY2025 N/A -$75.8M N/A $11.9M —
Context Therapeutics Inc. CNTX FY2025 N/A -$36.1M N/A $15.5M —
Tvardi Therapeutics, Inc. TVRD FY2025 N/A -$18.2M N/A $12.6M —
aTyr Pharma, Inc. ATYR FY2025 $190K -$74.1M N/A $9.4M —
Akari Therapeutics plc AKTX FY2025 N/A -$17.3M N/A $15.6M —
Citius Pharmaceuticals Inc. CTXR FY2025 N/A -$37.4M N/A $13.6M —

Frequently Asked Questions

No, Jasper Therapeutics, Inc. (JSPR) reported a net loss of $157.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $75.8M.

Jasper Therapeutics, Inc. (JSPR) reported diluted earnings per share of -$118.50 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jasper Therapeutics, Inc. (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Jasper Therapeutics, Inc. (JSPR) has a return on equity of -1826.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Jasper Therapeutics, Inc. (JSPR) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Jasper Therapeutics, Inc. (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Jasper Therapeutics, Inc. (JSPR) invested $63.1M in research and development during fiscal year 2025.

Jasper Therapeutics, Inc. (JSPR) had 933,227 shares outstanding as of fiscal year 2025.

Jasper Therapeutics, Inc. (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.

Jasper Therapeutics, Inc. (JSPR) had a liabilities-to-equity ratio of 7.62 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Jasper Therapeutics, Inc. (JSPR) had a return on assets of -211.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Jasper Therapeutics, Inc. (JSPR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $11.9M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Jasper Therapeutics, Inc. (JSPR) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $11.9M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Jasper Therapeutics, Inc. (JSPR) held $28.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $77.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Jasper Therapeutics, Inc. (JSPR) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Jasper Therapeutics, Inc. (JSPR) reported a net loss of $75.8M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top